Hopkinton, MA, United States of America

Robert Scannevin

USPTO Granted Patents = 9 

 

Average Co-Inventor Count = 12.4

ph-index = 2

Forward Citations = 12(Granted Patents)


Company Filing History:


Years Active: 2010-2025

Loading Chart...
Loading Chart...
9 patents (USPTO):

Title: Inventor Robert Scannevin: Innovating Solutions for Neurological Disorders

Introduction: Robert Scannevin, an accomplished inventor based in Hopkinton, MA, has made significant contributions to the field of neurology through his innovative research and development of compounds aimed at treating neurological disorders. With a portfolio of seven patents, Scannevin is dedicated to advancing medical treatments for conditions that impact millions of lives.

Latest Patents: Robert Scannevin's latest patents focus on promising compounds and methods for treating various neurological disorders. The primary invention features compounds useful in the treatment of conditions such as amyotrophic lateral sclerosis, frontotemporal degeneration, and Alzheimer's disease. By employing these compounds, either alone or in conjunction with other active agents, his research aims to treat or prevent the progression of these debilitating disorders.

Furthermore, Scannevin has developed compositions and methods specifically targeting neurological disorders associated with TAR-DNA binding protein (TDP)-43 aggregation. One of his key approaches involves administering an inhibitor of cytochrome P450 isoform 51A1 (CYP51A1). This may include small molecules or compounds that target CYP51A1 expression, providing a potential avenue for alleviating symptoms and addressing the underlying causes of these disorders.

Career Highlights: Throughout his career, Robert Scannevin has collaborated with prominent pharmaceutical companies, including Janssen Pharmaceutica and Yumanity Therapeutics, Inc. His work has led to significant advancements in the understanding and treatment of neurological diseases, demonstrating his commitment to improving patient outcomes and supporting innovative medical solutions.

Collaborations: Scannevin has worked alongside notable colleagues such as Kenneth Rhodes and Paul F. Jackson. Their collaborative efforts have furthered research and development in the field, contributing to the successful progression of groundbreaking therapies.

Conclusion: Robert Scannevin exemplifies the spirit of innovation through his dedication to advancing treatment options for neurological disorders. With multiple patents to his name and a proven track record of collaboration in the pharmaceutical industry, Scannevin continues to make strides in his field, enhancing the quality of life for patients suffering from chronic neurological conditions. His work represents a beacon of hope for those affected by these challenging diseases.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…